89 related articles for article (PubMed ID: 12542890)
21. Functional induction and de-induction of P-glycoprotein by St. John's wort and its ingredients in a human colon adenocarcinoma cell line.
Tian R; Koyabu N; Morimoto S; Shoyama Y; Ohtani H; Sawada Y
Drug Metab Dispos; 2005 Apr; 33(4):547-54. PubMed ID: 15640377
[TBL] [Abstract][Full Text] [Related]
22. The main components of St John's Wort inhibit low-density lipoprotein atherogenic modification: a beneficial "side effect" of an OTC antidepressant drug?
Laggner H; Schreier S; Hermann M; Exner M; Mühl A; Gmeiner BM; Kapiotis S
Free Radic Res; 2007 Feb; 41(2):234-41. PubMed ID: 17364950
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of human cytochrome P450 enzymes by constituents of St. John's Wort, an herbal preparation used in the treatment of depression.
Obach RS
J Pharmacol Exp Ther; 2000 Jul; 294(1):88-95. PubMed ID: 10871299
[TBL] [Abstract][Full Text] [Related]
24. Quantitative analysis of the active components and the by-products of eight dry extracts of Hypericum perforatum L. (St John's Wort).
von Eggelkraut-Gottanka SG; Abu Abed S; Müller W; Schmidt PC
Phytochem Anal; 2002; 13(3):170-6. PubMed ID: 12099108
[TBL] [Abstract][Full Text] [Related]
25. St. John's Wort: is it effective and harmless?
Biron CR
RDH; 1999 Jun; 19(6):74-6. PubMed ID: 10895712
[No Abstract] [Full Text] [Related]
26. Optimized and Validated HPLC Analysis of St. John's Wort Extract and Final Products by Simultaneous Determination of Major Ingredients.
Zeliou K; Kontaxis NI; Margianni E; Petrou C; Lamari FN
J Chromatogr Sci; 2017 Sep; 55(8):805-812. PubMed ID: 28472287
[TBL] [Abstract][Full Text] [Related]
27. Quantitative characterization of direct P-glycoprotein inhibition by St John's wort constituents hypericin and hyperforin.
Wang EJ; Barecki-Roach M; Johnson WW
J Pharm Pharmacol; 2004 Jan; 56(1):123-8. PubMed ID: 14980009
[TBL] [Abstract][Full Text] [Related]
28. Antidepressant activity of hyperforin conjugates of the St. John's wort, Hypericum perforatum Linn.: an experimental study.
Muruganandam AV; Bhattacharya SK; Ghosal S
Indian J Exp Biol; 2001 Dec; 39(12):1302-4. PubMed ID: 12018529
[TBL] [Abstract][Full Text] [Related]
29. Investigation of pharmacokinetic data of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin revealed from single and multiple oral dose studies with a hypericum extract containing tablet in healthy male volunteers.
Schulz HU; Schürer M; Bässler D; Weiser D
Arzneimittelforschung; 2005; 55(10):561-8. PubMed ID: 16294501
[TBL] [Abstract][Full Text] [Related]
30. Quantitative analysis of the major constituents of St John's wort with HPLC-ESI-MS.
Chandrasekera DH; Welham KJ; Ashton D; Middleton R; Heinrich M
J Pharm Pharmacol; 2005 Dec; 57(12):1645-52. PubMed ID: 16354409
[TBL] [Abstract][Full Text] [Related]
31. Secondary metabolites of Hypericum confertum and their possible chemotaxonomic significance.
Cirak C; Radusiene J; Janulis V; Ivanauskas L
Nat Prod Commun; 2010 Jun; 5(6):897-8. PubMed ID: 20614818
[TBL] [Abstract][Full Text] [Related]
32. Fast high-performance liquid chromatographic analysis of naphthodianthrones and phloroglucinols from Hypericum perforatum extracts.
Tolonen A; Hohtola A; Jalonen J
Phytochem Anal; 2003; 14(5):306-9. PubMed ID: 14516003
[TBL] [Abstract][Full Text] [Related]
33. Hypericum perforatum--chemical profiling and quantitative results of St. John's Wort products by an improved high-performance liquid chromatography method.
Ganzera M; Zhao J; Khan IA
J Pharm Sci; 2002 Mar; 91(3):623-30. PubMed ID: 11920747
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of chemical stability of St. John's wort commercial extract and some preparations.
Bilia AR; Bergonzi MC; Morgenni F; Mazzi G; Vincieri FF
Int J Pharm; 2001 Feb; 213(1-2):199-208. PubMed ID: 11165108
[TBL] [Abstract][Full Text] [Related]
35. St. John's wort flavonoids and their metabolites show antidepressant activity and accumulate in brain after multiple oral doses.
Paulke A; Nöldner M; Schubert-Zsilavecz M; Wurglics M
Pharmazie; 2008 Apr; 63(4):296-302. PubMed ID: 18468390
[TBL] [Abstract][Full Text] [Related]
36. 2.1 A crystal structure of human PXR in complex with the St. John's wort compound hyperforin.
Watkins RE; Maglich JM; Moore LB; Wisely GB; Noble SM; Davis-Searles PR; Lambert MH; Kliewer SA; Redinbo MR
Biochemistry; 2003 Feb; 42(6):1430-8. PubMed ID: 12578355
[TBL] [Abstract][Full Text] [Related]
37. Metabolome classification of commercial Hypericum perforatum (St. John's Wort) preparations via UPLC-qTOF-MS and chemometrics.
Farag MA; Wessjohann LA
Planta Med; 2012 Mar; 78(5):488-96. PubMed ID: 22271082
[TBL] [Abstract][Full Text] [Related]
38. Stimulation of hippocampal acetylcholine release by hyperforin, a constituent of St. John's Wort.
Kiewert C; Buchholzer ML; Hartmann J; Chatterjee SS; Klein J
Neurosci Lett; 2004 Jul; 364(3):195-8. PubMed ID: 15196674
[TBL] [Abstract][Full Text] [Related]
39. Liquid chromatography-mass spectrometry studies of St. John's wort methanol extraction: active constituents and their transformation.
Liu F; Pan C; Drumm P; Ang CY
J Pharm Biomed Anal; 2005 Feb; 37(2):303-12. PubMed ID: 15708671
[TBL] [Abstract][Full Text] [Related]
40. Investigation of the bioavailability of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin following single and multiple oral dosing of a hypericum extract containing tablet.
Schulz HU; Schürer M; Bässler D; Weiser D
Arzneimittelforschung; 2005; 55(1):15-22. PubMed ID: 15727160
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
